Neal Bradsher Purchases Shares in STAAR Surgical Company

Neal Bradsher has increased his stake in STAAR Surgical Company (NasdaqGM: STAA) by buying 11,145 shares on June 18, 2026. The transaction did not occur under a pre-planned trading program. Shares of STAAR Surgical traded at $28.83 on Tuesday.

Other Institutional Activity in STAAR Surgical Company

Broadwood Capital Inc grew its holdings by 1,104,351 shares, ending with 16,123,842 shares valued at about $301.5 million, a 7.4% increase. BlackRock, Inc. reduced its position by 694,217 shares, now holding 6,666,118 shares worth approximately $124.7 million, a 9.4% decrease. Yunqi Capital Ltd added 750,000 shares, bringing its total to 3,257,130 shares valued at around $60.9 million, a 29.9% increase. Madison Avenue Partners, LP opened a new position with 2,441,678 shares worth about $45.7 million, as did Vanguard Portfolio Management LLC, with 2,123,589 shares valued at approximately $39.7 million. State Street Corp reduced its stake by 107,443 shares, holding 1,832,996 shares valued at about $34.3 million, a 5.5% decrease.

STAAR Surgical Company Stock Up 30.4%

Shares of STAAR Surgical Company (NasdaqGM: STAA) traded near $28.83 on Tuesday. The company has a market capitalization of approximately $1.45 billion and a forward P/E ratio of 29.49. With a beta of 1.234, the stock's 52-week range has been between $15.59 and $35.87. The 50-day moving average is $28.33, and the 200-day moving average is $24.39. STAAR Surgical maintains a strong financial position with a current ratio of 5.12 and a quick ratio of 4.09, alongside a low debt-to-equity ratio of 10.58.

Recent Earnings

STAAR Surgical reported revenues of $290.4 million, reflecting a growth rate of 1.2%. Despite this, the company posted a net margin of -7.24% and a return on equity of -5.99%. The next earnings release is scheduled for August 12, 2026.

Insider Buying and Selling at STAAR Surgical Company

On June 18, 2026, several insiders made transactions involving STAAR Surgical Company stock. Jiang Wei sold 10,683 shares and bought 6,182 shares, while Richard Lebuhn purchased 11,145 shares. Arthur Butcher acquired 3,709 shares, and Lou Silverman both sold and bought 10,683 shares.

Analysts Set New Price Targets

On May 15, 2026, Wells Fargo maintained a 'hold' rating with a price target of $25. Canaccord Genuity, on May 14, 2026, maintained a 'buy' rating with a target of $32, while Piper Sandler kept a 'hold' rating with a target of $33. Stifel also maintained a 'hold' rating with a $31 target. Wedbush upgraded the stock to 'buy' with a $40 price target on the same day. The consensus among analysts is mixed, with a mean price target of $29.67 based on nine opinions.

About STAAR Surgical Company

STAAR Surgical Company, headquartered in Lake Forest, California, is a healthcare firm specializing in designing, developing, and selling implantable lenses for eye surgery. The company’s products, including the EVO ICL series, address visual disorders like myopia and astigmatism. STAAR Surgical markets its products through direct sales in countries like Japan and the United States, and through distributors in regions including China and Europe. The company employs 921 people and is led by CEO Deborah J. Andrews.

Bottom Line

Neal Bradsher's recent purchase of STAAR Surgical Company shares is a notable insider move. Investors often watch insider trades for potential signals, though it's important to remember these transactions may not reflect current market conditions. STAAR Surgical continues to be a player in the medical instruments industry, with analysts offering varied outlooks on its stock performance.